| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© Oxford University Press 2007.
NEWS |
Preliminary Breast Cancer Vaccine Study Shows Promise
| The first 10% of the full text of this article appears below. |
A vaccine designed to treat breast cancer has performed surprisingly well in an initial clinical study.
In a phase II trial of 186 patients, the vaccine targeting the HER2/neu E75 peptide reduced the risk of recurrence by 50% in 101 breast cancer patients who were clinically disease free after treatment compared with those who were not treated with the vaccine. Immunized patients also had about a 20% improvement in disease-free survival, according to a presentation at the San Antonio Breast Cancer Symposium in December, though
The Future of an E75 Vaccine
![]()
CiteULike
Connotea
Del.icio.us What's this?
This article has been cited by other articles:
![]() |
I. O-Sullivan, A. Chopra, J. Carr, T. S. Kim, and E. P. Cohen Immunity to Growth Factor Receptor-Bound Protein 10, a Signal Transduction Molecule, Inhibits the Growth of Breast Cancer in Mice Cancer Res., April 1, 2008; 68(7): 2463 - 2470. [Abstract] [Full Text] [PDF] |
||||
